Showing results (1-10 of 10,496) with videos related to
Sort By:
Pageof 1,050
Pharmaceutical Statistics|December 22, 2021
A targeted simulation-extrapolation method for evaluating biomarkers based on new technologies in precision medicineDong Wang, Sue-Jane Wang, Joshua Xu, et al.Journal of Biopharmaceutical Statistics|October 11, 2023
The impact of misclassification errors on the performance of biomarkers based on next-generation sequencing, a simulation studyDong Wang, Sue-Jane Wang, Samir LababidiJournal of Biopharmaceutical Statistics|December 29, 2007
Challenges in DNA microarray studies from the regulatory perspectiveSamir LababidiJournal of the Formosan Medical Association = Taiwan Yi Zhi|January 9, 2009
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development programSue-Jane WangPharmaceutical Statistics|October 25, 2007
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSISue-Jane WangContemporary Clinical Trials|August 10, 2020
Recent advances in clinical trial design considerations in Thera"nostics"Sue-Jane WangJournal of Biopharmaceutical Statistics|November 9, 2010
Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issuesSue-Jane WangBiomarkers in Medicine|September 15, 2023
US FDA public meeting: identification of concepts and terminology for multicomponent biomarkersAbena S Agyeman, Abbas Bandukwala, Khaled Bouri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trialsYuan Ji, Sue-Jane WangJournal of Biopharmaceutical Statistics|January 8, 2014
Standardization for subgroup analysis in randomized controlled trialsRavi Varadhan, Sue-Jane WangPageof 1,050